Patents by Inventor John Lydeard

John Lydeard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION
    Publication number: 20240110189
    Abstract: This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CLL1 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 4, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Chong Luo, Michelle Lin, Jessica Evelyn Lisle
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11903973
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: February 20, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • COMPOSITIONS AND METHODS FOR CD5 MODIFICATION
    Publication number: 20240041932
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD5, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD5 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 14, 2021
    Publication date: February 8, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Tirtha Chakraborty
  • COMPOSITIONS AND METHODS FOR CD7 MODIFICATION
    Publication number: 20240033290
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD7, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD7 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 1, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Julia Etchin, Michael Pettiglio, Tirtha Chakraborty
  • COMPOSITIONS AND METHODS FOR TREATING HEMATOPOIETIC MALIGNANCY
    Publication number: 20240000846
    Abstract: Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.
    Type: Application
    Filed: October 27, 2021
    Publication date: January 4, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Christopher Slapak, Glen Raffel, Michelle Lin, John Lydeard, Tirtha Chakraborty
  • COMPOSITIONS AND METHODS FOR CD38 MODIFICATION
    Publication number: 20230398219
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD38, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD38 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 14, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
  • COMPOSITIONS AND METHODS FOR CD6 MODIFICATION
    Publication number: 20230364233
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD6, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD6 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 28, 2021
    Publication date: November 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
  • COMPOSITIONS AND METHODS FOR CD30 GENE MODIFICATION
    Publication number: 20230364146
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD30, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD30 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20230053285
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11571445
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: February 7, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11559551
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: January 24, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • COMPOSITIONS AND METHODS FOR CD123 MODIFICATION
    Publication number: 20220333116
    Abstract: This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD123 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Chonh Luo, Bibhu Prasad Mishra, Michelle Lin
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11464807
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 11, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION
    Publication number: 20220290160
    Abstract: This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CLL1 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 15, 2022
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Chong Luo, Michelle Lin
  • COMPOSITIONS AND METHODS FOR CD33 MODIFICATION
    Publication number: 20220228153
    Abstract: Some aspects of this disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD33 gene. Some aspects of the disclosure provide compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 21, 2022
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Bibhu Prasad Mishra
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11382932
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 12, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20220008476
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: February 16, 2021
    Publication date: January 13, 2022
    Applicant: VOR BIOPHARMA, INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210315936
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 14, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210236559
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 5, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard